PROCEPT BioRobotics Corporation Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2023
January 08, 2024 at 05:00 pm
Share
PROCEPT BioRobotics Corporation provided preliminary unaudited revenue guidance for the fourth quarter and fiscal year ended December 31, 2023. For the quarter, the company expects total revenue to be in the range of $43.3 million to $43.6 million, compared to $23.8 million in the prior year period.
For the fiscal year, the company expects revenue to be approximately $135.9 million to $136.2 million, representing growth of approximately 81% to 82% compared to the prior year period.
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Companyâs proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.
PROCEPT BIOROBOTICS CORPORATION 
